Osteogenesis Imperfecta Treatment Market Report 2026

The osteogenesis imperfecta treatment market size has grown steadily in recent years. It will grow from $0.93 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to limited treatment options for osteogenesis imperfecta, reliance on conventional bisphosphonate therapy, low patient awareness about lifestyle management, restricted access to specialized surgical interventions, limited homecare support infrastructure.

The osteogenesis imperfecta treatment market size is expected to see steady growth in the next few years. It will grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to development of novel drugs and hormone therapies, advancements in minimally invasive rodding and spinal surgeries, integration of telemedicine in homecare, increasing focus on patient-centric lifestyle and rehabilitation programs, rising adoption of precision medicine approaches. Major trends in the forecast period include increased adoption of bisphosphonate and teriparatide therapies, growth in rodding and spinal fusion surgeries, rising demand for personalized physical therapy programs, expansion of homecare and specialty clinic services, enhanced focus on patient education and lifestyle management.

The rising prevalence of osteogenesis imperfecta (OI) is anticipated to drive the growth of the osteogenesis imperfecta treatment market in the coming years. Osteogenesis imperfecta is a genetic condition marked by brittle bones that fracture easily and affects individuals of all ages. The increase in osteogenesis imperfecta prevalence is largely attributed to improvements in genetic testing and the development of national and regional disease registries, which have enabled the identification of previously undiagnosed cases. Osteogenesis imperfecta treatments support patients through interventions such as bisphosphonates, intramedullary rods, braces, and supportive care services that help enhance bone strength and improve quality of life. For instance, in July 2025, according to Oxford Academic, a UK-based academic research platform, out of 5,722 individuals with two or more osteogenesis imperfecta-related medical claims recorded at least 30 days apart, 2,095 met the CE eligibility criteria and formed the overall OI study cohort. Therefore, the growing prevalence of osteogenesis imperfecta is fueling the expansion of the osteogenesis imperfecta treatment market.

Major companies operating in the osteogenesis imperfecta treatment market are concentrating on advanced therapeutic approaches, such as sclerostin inhibition therapy, to stimulate bone formation and lower fracture risk in patients with osteogenesis imperfecta (OI). Sclerostin inhibition therapy uses monoclonal antibodies to block sclerostin, a protein that limits bone growth, thereby increasing bone mineral density and structural strength. For example, in October 2024, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its investigational treatment setrusumab (UX143). Setrusumab is a fully human monoclonal antibody developed to inhibit sclerostin, promoting new bone formation and improving bone strength with the goal of reducing fracture risk in patients aged two years and older with OI Types I, III, and IV.

In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company, acquired a 97.09% ownership stake in EffRx Pharmaceuticals SA, a Swiss specialty pharmaceutical firm. Through this acquisition, Abiogen seeks to accelerate its international growth strategy and reinforce its portfolio in bone-related diseases, particularly within musculoskeletal and rare disorder segments. EffRx Pharmaceuticals SA is a Switzerland-based company engaged in the development and commercialization of prescription medicines for musculoskeletal and rare conditions.

Major companies operating in the osteogenesis imperfecta treatment market are Amgen Inc., Ascendis Pharma A/S, Mereo BioPharma Group PLC, OrthoPediatrics Corp., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Kyowa Kirin Co. Ltd., Ipsen S.A., Alexion Pharmaceuticals (AstraZeneca Rare Disease), Takeda Pharmaceutical Company Limited, Novartis AG (Bone Metabolism Portfolio), Roche Holding AG (Genentech), Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Stada Arzneimittel AG, Fresenius Kabi AG, Alkem Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Pfizer Inc., Viatris Inc., Accord Healthcare Ltd., Sandoz Group AG, Medtronic plc, Smith & Nephew plc, Zimmer Biomet Holdings Inc.

North America was the largest region in the osteogenesis imperfecta treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteogenesis imperfecta treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteogenesis imperfecta treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the osteogenesis imperfecta treatment market by increasing the cost of imported pharmaceuticals, surgical implants, and medical devices. Segments such as teriparatide, rodding surgery equipment, and specialized rehabilitation devices are most affected, particularly in Asia-Pacific regions like China and India where import duties are significant. This has led to higher treatment costs and supply chain challenges. Positively, tariffs have encouraged local manufacturing, innovation in drug delivery systems, and domestic production of surgical and rehabilitation equipment.

The osteogenesis imperfecta treatment market research report is one of a series of new reports that provides osteogenesis imperfecta treatment market statistics, including osteogenesis imperfecta treatment industry global market size, regional shares, competitors with a osteogenesis imperfecta treatment market share, detailed osteogenesis imperfecta treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteogenesis imperfecta treatment industry. This osteogenesis imperfecta treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Osteogenesis imperfecta treatment encompasses a range of medical, surgical, and supportive approaches aimed at controlling symptoms, improving bone strength, lowering the risk of fractures, and enhancing the overall quality of life of individuals with osteogenesis imperfecta (OI), a genetic condition marked by fragile bones.

The primary treatment types for osteogenesis imperfecta include medication, surgery, physical therapy, and lifestyle modifications. Medication involves the use of pharmaceutical agents to manage or treat the condition. In osteogenesis imperfecta, drugs such as bisphosphonates, teriparatide, and monoclonal antibodies are used to strengthen bones and decrease fracture frequency. The different drug classes include teriparatide, denosumab, and others, administered through various routes such as subcutaneous, intravenous, oral, and additional methods. These treatments are supplied through distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by end users such as hospitals, homecare settings, specialty clinics, and other healthcare providers.

The osteogenesis imperfecta treatment market consists of revenues earned by entities by providing services such as physical therapy, occupational therapy, and orthopedic support. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteogenesis imperfecta treatment market also includes sales of bisphosphonates, intramedullary rods, and braces and splints. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.